Valuation: C4 Therapeutics, Inc.

Market Cap 39Cr 35Cr 33Cr 30Cr 55Cr 3.76TCr 56Cr 391.66Cr 156Cr 1.97TCr 148.19Cr 145.07Cr 6.25TCr P/E 2026 *
-3.77x
P/E 2027 * -3.4x
Enterprise Value 31Cr 28Cr 26Cr 24Cr 44Cr 2.99TCr 45Cr 311.04Cr 123.89Cr 1.56TCr 117.69Cr 115.21Cr 4.96TCr EV / Sales 2026 *
11.9x
EV / Sales 2027 * 12.5x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+5.76%
1 week+7.10%
Current month+1.95%
1 month+8.99%
3 months-4.37%
6 months+23.45%
Current year+77.75%
1 week 2.94
Extreme 2.94
3.53
1 month 2.59
Extreme 2.59
3.53
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Founder

3,662 0.0030%
01/10/26 Free

Director

4,618 0.0038%
18/09/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+5.76%+7.10%+31.59%+124.83% 39Cr
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+1.76%+2.10%+12.10%+81.21% 5.45TCr
-0.94%+0.77%+8.85%+100.19% 5.36TCr
+2.76%+0.87%+27.92%+57.51% 4.48TCr
+2.00%-3.39%+17.83%+100.08% 4.16TCr
+1.34%-2.86%+224.43%+928.45% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+29.06%+48.65%+106.84%+92.73% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +4.66%+4.15%+49.91%+158.81% 3.81TCr
Weighted average by Cap. +3.22%+2.66%+47.33%+161.15%

Financials

2026 *2027 *
Net sales 2.64Cr 2.37Cr 2.19Cr 1.98Cr 3.71Cr 251.43Cr 3.75Cr 26Cr 10Cr 131.57Cr 9.91Cr 9.7Cr 417.68Cr 2.23Cr 2Cr 1.85Cr 1.67Cr 3.13Cr 212.25Cr 3.17Cr 22Cr 8.8Cr 111.07Cr 8.36Cr 8.19Cr 352.59Cr
Net income -11Cr -10Cr -9.38Cr -8.5Cr -16Cr -1.08TCr -16Cr -112.17Cr -45Cr -563.69Cr -42Cr -42Cr -1.79TCr -15Cr -13Cr -12Cr -11Cr -20Cr -1.39TCr -21Cr -144.7Cr -58Cr -727.14Cr -55Cr -54Cr -2.31TCr
Net Debt -8.13Cr -7.29Cr -6.74Cr -6.11Cr -11Cr -774.21Cr -12Cr -81Cr -32Cr -405.13Cr -31Cr -30Cr -1.29TCr -12Cr -11Cr -9.72Cr -8.8Cr -16Cr -1.12TCr -17Cr -116.19Cr -46Cr -583.85Cr -44Cr -43Cr -1.85TCr
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
29/26/29 $3.395 +5.76% 41,05,806
27/26/27 $3.210 +7.72% 41,19,734
26/26/26 $2.980 -2.61% 31,79,137
23/26/23 $3.060 -3.77% 47,41,850
22/26/22 $3.180 +0.32% 16,92,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.210USD
Average target price
12.86USD
Spread / Average Target
+300.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock